Federation des caisses Desjardins du Quebec’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-18,000
| Closed | -$312K | – | 2656 |
|
|
2021
Q3 | $312K | Sell |
18,000
-150
| -0.8% | -$1.75K | ﹤0.01% | 1033 |
|
|
2021
Q2 | $175K | Hold |
18,150
| – | – | ﹤0.01% | 1224 |
|
|
2021
Q1 | $193K | Sell |
18,150
-216
| -1% | -$2.67K | ﹤0.01% | 1137 |
|
|
2020
Q4 | $267K | Buy |
18,366
+1,000
| +6% | +$14.4K | ﹤0.01% | 974 |
|
|
2020
Q3 | $246K | Hold |
17,366
| – | – | ﹤0.01% | 822 |
|
|
2020
Q2 | $140K | Buy |
17,366
+300
| +2% | +$1.86K | ﹤0.01% | 933 |
|
|
2020
Q1 | $66.5K | Sell |
17,066
-13,000
| -43% | -$49.1K | ﹤0.01% | 1160 |
|
|
2019
Q4 | $29.7K | Buy |
30,066
+30,000
| +45,455% | +$11.5K | ﹤0.01% | 1641 |
|
|
2019
Q3 | $20 | Hold |
66
| – | – | ﹤0.01% | 2264 |
|
|
2019
Q2 | $19 | Hold |
66
| – | – | ﹤0.01% | 2245 |
|
|
2019
Q1 | $42 | Hold |
66
| – | – | ﹤0.01% | 2059 |
|
|
2018
Q4 | $113 | Hold |
66
| – | – | ﹤0.01% | 2047 |
|
|
2018
Q3 | $367 | Hold |
66
| – | – | ﹤0.01% | 2089 |
|
|
2018
Q2 | $379 | Hold |
66
| – | – | ﹤0.01% | 2110 |
|
|
2018
Q1 | $466 | Hold |
66
| – | – | ﹤0.01% | 2094 |
|
|
2017
Q4 | $456 | Sell |
66
-2,666
| -98% | -$22.1K | ﹤0.01% | 2080 |
|
|
2017
Q3 | $13.6K | Hold |
2,732
| – | – | ﹤0.01% | 1604 |
|
|
2017
Q2 | $11.8K | Buy |
2,732
+66
| +2% | +$365 | ﹤0.01% | 1688 |
|
|
2017
Q1 | $16.1K | Buy |
+2,666
| New | +$15.6K | ﹤0.01% | 1338 |
|
Other funds holding TRIL
Federation des caisses Desjardins du Quebec's TRIL Position: Q4 2021 in Review
Federation des caisses Desjardins du Quebec sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 18,000 shares — an estimated $312K sold.
Federation des caisses Desjardins du Quebec first reported a position in TRIL in Q1 2017 and held it in 19 quarters. The position peaked at $312K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Federation des caisses Desjardins du Quebec reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Federation des caisses Desjardins du Quebec sold 18,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $312K.
- Federation des caisses Desjardins du Quebec first reported a position in Trillium Therapeutics Inc. in Q1 2017 and held it in 19 quarters.
- Federation des caisses Desjardins du Quebec's Trillium Therapeutics Inc. position peaked at $312K in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2021, filed 30 Aug 2024.